Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
EASL International Liver Congress (ILC) 2022: virale hepatitis in de spotlights
jul 2022 | Hepatitis, Vaccinatie